Protagonist Therapeutics, Inc.
PTGX
$65.14
-$2.28-3.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -198.34% | -108.85% | 496.49% | -8.47% | -114.77% |
| Total Depreciation and Amortization | 7.92% | 50.75% | -17.16% | -27.47% | 8.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -21.88% | 81.87% | -13.57% | 0.62% | -5.88% |
| Change in Net Operating Assets | -103.11% | 174.34% | -6,284.51% | -100.90% | 219.62% |
| Cash from Operations | -122.96% | 529.65% | -4.72% | -110.37% | 1,079.34% |
| Capital Expenditure | -49.17% | -75.81% | 60.00% | -2,667.86% | 88.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 159.26% | -1,015.35% | 95.95% | -136.05% | -1,495.39% |
| Cash from Investing | 158.06% | -981.97% | 95.82% | -136.85% | -1,551.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -75.47% | 195.76% | -66.55% | 368.55% | -67.02% |
| Repurchase of Common Stock | 100.00% | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -74.44% | 183.87% | -66.55% | 368.55% | -64.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -31.72% | 225.19% | 84.91% | -222.64% | 1,392.99% |